{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:25:29Z","timestamp":1794547529258,"version":"4.9.1"},"reference-count":40,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T00:00:00Z","timestamp":1500940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI111990"],"award-info":[{"award-number":["R01AI111990"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI090155"],"award-info":[{"award-number":["R01AI090155"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mBio"],"published-print":{"date-parts":[[2017,9,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The rapid increase of carbapenem resistance in Gram-negative bacteria has resurrected the importance of the polymyxin antibiotics. The recent discovery of plasmid-mediated polymyxin resistance (\n            <jats:italic>mcr<\/jats:italic>\n            -\n            <jats:italic>1<\/jats:italic>\n            ) in carbapenem-resistant\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            serves as an important indicator that the golden era of antibiotics is under serious threat. We assessed the bacterial killing of 15 different FDA-approved antibiotics alone and in combination with polymyxin B in time-killing experiments against\n            <jats:italic>Escherichia coli<\/jats:italic>\n            MCR1_NJ, the first reported isolate in the United States to coharbor\n            <jats:italic>mcr-1<\/jats:italic>\n            and a New Delhi metallo-\u03b2-lactamase gene (\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>NDM-5<\/jats:sub>\n            ). The most promising regimens were advanced to the hollow-fiber infection model (HFIM), where human pharmacokinetics for polymyxin B, aztreonam, and amikacin were simulated over 240\u00a0h. Exposure to polymyxin B monotherapy was accompanied by MCR1_NJ regrowth but not resistance amplification (polymyxin B MIC from 0 to 240\u00a0h [MIC\n            <jats:sub>0h<\/jats:sub>\n            to MIC\n            <jats:sub>240h<\/jats:sub>\n            ] of 4\u00a0mg\/liter), whereas amikacin monotherapy caused regrowth and simultaneous resistance amplification (amikacin MIC\n            <jats:sub>0h<\/jats:sub>\n            of 4 mg\/liter versus MIC\n            <jats:sub>240h<\/jats:sub>\n            of &gt;64 mg\/liter). No MCR1_NJ colonies were observed for any of the aztreonam-containing regimens after 72\u00a0h. However, HFIM cartridges for both aztreonam monotherapy and the polymyxin B-plus-aztreonam regimen were remarkably turbid, and the presence of long, filamentous MCR1_NJ cells was evident in scanning electron microscopy, suggestive of a nonreplicating persister (NRP) phenotype. In contrast, the 3-drug combination of polymyxin B, aztreonam, and amikacin provided complete eradication (&gt;8-log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml reduction) with suppression of resistance and prevention of NRP formation. This is the first comprehensive pharmacokinetic\/pharmacodynamic study to evaluate triple-drug combinations for polymyxin- and carbapenem-resistant\n            <jats:italic>E.\u00a0coli<\/jats:italic>\n            coproducing MCR-1 and NDM-5 and will aid in the preparation for a so-called \u201cpostantibiotic\u201d era.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>IMPORTANCE<\/jats:bold>\n            A global health crisis may be on the horizon, as the golden era of antibiotics is under serious threat. We recently reported the first case in the United States of a highly resistant,\n            <jats:italic>Escherichia coli<\/jats:italic>\n            so-called \u201csuperbug\u201d (MCR1_NJ), coharboring two of the most worrying antibiotic resistance genes, encoding mobile colistin resistance (\n            <jats:italic>mcr<\/jats:italic>\n            -\n            <jats:italic>1<\/jats:italic>\n            ) and a New Delhi metallo-\u03b2-lactamase (\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>NDM-5<\/jats:sub>\n            ). Worryingly, the medical community is vulnerable to this emerging bacterial threat because optimal treatment strategies are undefined. Here, we report the activity of an optimized combination using simulated human doses of commercially available antibiotics against MCR1_NJ. A unique triple combination involving a cocktail of polymyxin B, aztreonam, and amikacin eradicated the MCR-1- and NDM-5-producing\n            <jats:italic>E.\u00a0coli<\/jats:italic>\n            . Each antimicrobial agent administered as monotherapy or in double combinations failed to eradicate MCR1_NJ at a high inoculum. To our knowledge, this is the first study to propose 3-drug therapeutic solutions against superbugs coharboring\n            <jats:italic>mcr-1<\/jats:italic>\n            and\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>NDM<\/jats:sub>\n            , seeking to prepare clinicians for future occurrences of these pathogens.\n          <\/jats:p>","DOI":"10.1128\/mbio.00540-17","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:10:21Z","timestamp":1501027821000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["Polymyxin Combinations Combat\n            <i>Escherichia coli<\/i>\n            Harboring\n            <i>mcr-1<\/i>\n            and\n            <i>bla<\/i>\n            <sub>NDM-5<\/sub>\n            : Preparation for a Postantibiotic Era"],"prefix":"10.1128","volume":"8","author":[{"given":"Zackery P.","family":"Bulman","sequence":"first","affiliation":[{"name":"Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York, USA"},{"name":"School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[{"name":"Public Health Research Institute, New Jersey Medical School, Rutgers, the State University of New Jersey, Newark, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Satlin","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, Cornell University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Qian","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen B.","family":"Bulitta","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia N.","family":"Holden","sequence":"additional","affiliation":[{"name":"Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York, USA"},{"name":"School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Nation","sequence":"additional","affiliation":[{"name":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry N.","family":"Kreiswirth","sequence":"additional","affiliation":[{"name":"Public Health Research Institute, New Jersey Medical School, Rutgers, the State University of New Jersey, Newark, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York, USA"},{"name":"School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw475"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00424-7"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw274"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01191-16"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01319-16"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00440-16"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00056-6"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00057-8"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6601a7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep15082"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70318-9"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq179"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02301-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03649.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit152"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01480-13"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.07.020"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx121"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00152-3"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr180"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70143-2"},{"key":"e_1_3_2_23_2","first-page":"463","article-title":"Comparison of the inhibitory and bactericidal activity of aztreonam and amikacin against gram negative aerobic bacilli","volume":"18","author":"Fung-Tomc JC","year":"1988","unstructured":"Fung-Tomc JC Lincourt W Thater C Kessler RE . 1988. Comparison of the inhibitory and bactericidal activity of aztreonam and amikacin against gram negative aerobic bacilli. Ann Clin Lab Sci18:463\u2013467.","journal-title":"Ann Clin Lab Sci"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-50-13773"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)74210-3"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00056-10"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1097(03)00856-5"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.030932-0"},{"key":"e_1_3_2_29_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI Document M07-A10","author":"CLSI","year":"2015","unstructured":"CLSI . 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI Document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02377-15"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02831-15"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit334"},{"key":"e_1_3_2_33_2","volume-title":"Azactam (aztreonam injection) package insert","author":"Bristol-Myers Squibb Company","year":"2013","unstructured":"Bristol-Myers Squibb Company . 2013. Azactam (aztreonam injection) package insert. Bristol-Myers Squibb Company, Princeton, NJ."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.4.614"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/15.suppl_A.125"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.01.015"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02097-16"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp324"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp352"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-409"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.4161\/fly.19695"}],"container-title":["mBio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mBio.00540-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mBio.00540-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T02:27:26Z","timestamp":1646706446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mBio.00540-17"}},"subtitle":[],"editor":[{"given":"Gerard D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,9,6]]}},"alternative-id":["10.1128\/mBio.00540-17"],"URL":"https:\/\/doi.org\/10.1128\/mbio.00540-17","relation":{},"ISSN":["2161-2129","2150-7511"],"issn-type":[{"value":"2161-2129","type":"print"},{"value":"2150-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,6]]},"assertion":[{"value":"2017-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00540-17"}}